Kazia presented the results from a new interim data analysis of its ongoing Phase IIa study of paxalisib in glioblastoma multiforme (GBM). The data were consistent with previous data and showed progression-free survival (PFS) of 8.4 months and overall survival (OS) of 17.5 months. Importantly, Kazia also published some of the first safety data at the full 60mg dose, which show an attractive profile compared to other members of this class.
24 Nov 2020
Kazia Therapeutics - Phase IIa shows good safety, consistent efficacy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Kazia Therapeutics - Phase IIa shows good safety, consistent efficacy
- Published:
24 Nov 2020 -
Author:
Dr Nathaniel Calloway -
Pages:
6
Kazia presented the results from a new interim data analysis of its ongoing Phase IIa study of paxalisib in glioblastoma multiforme (GBM). The data were consistent with previous data and showed progression-free survival (PFS) of 8.4 months and overall survival (OS) of 17.5 months. Importantly, Kazia also published some of the first safety data at the full 60mg dose, which show an attractive profile compared to other members of this class.